Takeda Pharmaceutical Co Ltd ADR
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $1,187,097,000 | $1,219,900,000 | $1,114,648,916 | $1,213,211,320 |
Gross Profit | 795,004,000 | 813,224,000 | 543,810,164 | 660,345,606 |
EBITDA | 326,937,000 | 389,203,276 | 154,877,784 | 452,778,397 |
EBIT | 219,349,000 | 226,563,000 | -8,992,216 | 262,139,397 |
Net Income | 192,429,000 | 113,197,000 | -24,765,767 | 105,509,960 |
Net Change In Cash | 1,187,097,000 | 1,219,900,000 | 1,114,648,916 | 1,213,211,320 |
Free Cash Flow | 212,647,289 | 73,812,000 | 10,135,000 | 150,879,000 |
Cash | 418,533,000 | 460,982,000 | 597,634,849 | 655,384,084 |
Basic Shares | 3,209,442 | 3,209,442 | 3,124,984 | 3,204,936 |
Annual Financials
| Values in thousands | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
Revenue | $4,777,450,268 | $4,581,551,000 | $4,263,762,000 | $4,027,478,000 |
Gross Profit | 2,439,331,507 | 3,001,334,000 | 2,832,257,000 | 2,783,406,000 |
EBITDA | 1,376,143,835 | 1,210,512,000 | 1,227,477,000 | 1,284,067,000 |
EBIT | 655,016,835 | 449,116,000 | 499,475,000 | 619,667,000 |
Net Income | 203,326,753 | 107,928,000 | 144,067,000 | 317,017,000 |
Net Change In Cash | 4,777,450,268 | 4,581,551,000 | 4,263,762,000 | 4,027,478,000 |
Free Cash Flow | 626,772,000 | 677,557,000 | 235,614,000 | 343,467,000 |
Cash | 597,634,849 | 385,113,000 | 457,800,000 | 533,530,000 |
Basic Shares | 3,205,566 | 3,210,710 | 3,160,686 | 3,139,744 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $0.51 |
2026-06-30 | $0.48 |
2026-03-31 | -$0.74 |
2025-12-31 | $0.20 |